NASDAQ:FUSN • CA36118A1003
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for FUSION PHARMACEUTICALS INC (FUSN).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-04-16 | TD Cowen | Downgrade | Buy -> Hold |
| 2024-03-21 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-03-21 | Wedbush | Reiterate | Neutral -> Neutral |
| 2024-03-20 | JonesTrading | Downgrade | Buy -> Hold |
| 2024-03-20 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2024-03-20 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2024-03-20 | Raymond James | Downgrade | Strong Buy -> Market Perform |
| 2024-03-20 | Truist Securities | Downgrade | Buy -> Hold |
| 2024-03-19 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-03-19 | Brookline Capital | Downgrade | Buy -> Hold |
| 2024-03-19 | William Blair | Downgrade | Outperform -> Market Perform |
| 2024-03-19 | Wedbush | Downgrade | Outperform -> Neutral |
| 2024-03-19 | Raymond James | Downgrade | Strong Buy -> Market Perform |
| 2024-03-19 | Truist Securities | Downgrade | Buy -> Hold |
| 2024-03-19 | Jefferies | Downgrade | Buy -> Hold |
| 2024-03-04 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-01-26 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-01-05 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-01-05 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2023-12-27 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2023-12-27 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2023-12-20 | RBC Capital | Initiate | Outperform |
| 2023-10-03 | B. Riley Securities | Reiterate | Buy -> Buy |
| 2023-09-29 | Oppenheimer | Initiate | Outperform |
| 2023-08-28 | Raymond James | Maintains | Outperform -> Outperform |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.44M | 1.46M 1.39% | 2.068M 41.64% | 394.74K -80.91% | 409.316K 3.69% | 8.907M 2,076.07% | 582.277K -93.46% | 51.021M 8,662.32% | 335.49M 557.55% | 709.06M 111.35% | 1.136B 60.21% | |
| EBITDA YoY % growth | -81.39M -117.27% | -87.12M -7.04% | -97.887M -12.36% | -130.068M -32.88% | -151.818M -16.72% | -139.698M 7.98% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -82.02M -116.18% | -88.03M -7.33% | -99.232M -12.73% | -128.224M -29.22% | -142.924M -11.46% | -152.908M -6.99% | -185.317M -21.19% | -133.683M 27.86% | 81.185M 160.73% | 432.77M 433.07% | 718.63M 66.05% | |
| Operating Margin | -5,695.83% | -6,029.45% | -4,798.45% | -32,483.07% | -34,917.85% | -1,716.72% | -31,826.22% | -262.02% | 24.20% | 61.03% | 63.26% | |
| EPS YoY % growth | -1.90 31.89% | -2.00 -5.26% | -1.47 26.50% | -1.48 -0.46% | -1.71 -15.94% | -1.74 -1.67% | -1.71 1.56% | -1.07 37.35% | 1.19 211.16% | 2.94 146.44% | 4.41 50.06% |
All data in USD
| Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.37 3.82% | -0.37 -49.60% | -0.38 3.41% | -0.44 -10.50% | -0.45 -22.79% | -0.47 -25.45% | -0.48 -26.36% | -0.48 -8.46% | -0.48 -6.82% | -0.49 -4.35% | -0.50 -5.00% |
| Revenue Q2Q % growth | 162.517K 377.99% | 155.723K -92.24% | 165.444K | -100.00% | -100.00% | -100.00% | N/A | N/A | N/A | N/A | |
| EBITDA Q2Q % growth | -33.711M -29.16% | -33.711M -83.11% | -33.711M -25.18% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -31.391M -17.53% | -31.885M -64.44% | -32.844M -16.16% | -35.7M 0.45% | -36.21M -15.35% | -39.27M -23.16% | -39.78M -21.12% | N/A | N/A | N/A | N/A |
All data in USD
18 analysts have analysed FUSN and the average price target is 21.55 USD. This implies a price decrease of -0.01% is expected in the next year compared to the current price of 21.55.
FUSION PHARMACEUTICALS INC (FUSN) will report earnings on 2024-08-06, after the market close.
The consensus EPS estimate for the next earnings of FUSION PHARMACEUTICALS INC (FUSN) is -0.37 USD and the consensus revenue estimate is 162.52K USD.
The consensus rating for FUSION PHARMACEUTICALS INC (FUSN) is 70 / 100 . This indicates that analysts generally have a neutral outlook on the stock.